Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vaxxas, Inc.
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
A leading Australian venture capital firm has raised the largest ever amount for a private investment fund in the life sciences sector in the country, which will support both early- and mid-stage biotech and device research.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced January through February 2015.
At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.
- Medical Devices
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Vaxxas Pty Ltd